2023
DOI: 10.3389/fpsyt.2023.1267495
|View full text |Cite
|
Sign up to set email alerts
|

Case report: Rapid improvements of anorexia nervosa and probable myalgic encephalomyelitis/chronic fatigue syndrome upon metreleptin treatment during two dosing episodes

Johannes Hebebrand,
Jochen Antel,
Linda von Piechowski
et al.

Abstract: A comorbidity of anorexia nervosa (AN) and myalgic encephalomyelitis (ME/CSF) is uncommon. A 17 years-old male adolescent with possible onset of ME/CFS after an Epstein Barr Virus infection (EBV) and later onset of AN during a second period of weight loss was twice treated off-label with metreleptin for 15 and 11 days, respectively. As in previous cases, eating disorder specific cognitions and mood improved. Interestingly, fatigue and post-exertional muscle pain (P-EMP) improved, too. We discuss potential mech… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 44 publications
(30 reference statements)
0
1
0
Order By: Relevance
“…The hypothesis that leptin plays a substantial role in entrapment has been supported by a Mendelian randomization study linking a low leptin level to an increased risk for development of AN (Peters, Antel, et al, 2021). Further, recent case reports of off-label treatment with recombinant human leptin (metreleptin) have entailed clinical improvements and the lessening of entrapment in patients with both AN (Antel et al, 2021;Gradl-Dietsch et al, 2023;Hebebrand, Antel, von Piechowski, et al, 2023;Milos et al, 2020) and atypical AN (Hebebrand, Antel, & Peters, 2023).…”
Section: Mechanisms Underlying Prediction Of Weight Loss By Premorbid...mentioning
confidence: 99%
“…The hypothesis that leptin plays a substantial role in entrapment has been supported by a Mendelian randomization study linking a low leptin level to an increased risk for development of AN (Peters, Antel, et al, 2021). Further, recent case reports of off-label treatment with recombinant human leptin (metreleptin) have entailed clinical improvements and the lessening of entrapment in patients with both AN (Antel et al, 2021;Gradl-Dietsch et al, 2023;Hebebrand, Antel, von Piechowski, et al, 2023;Milos et al, 2020) and atypical AN (Hebebrand, Antel, & Peters, 2023).…”
Section: Mechanisms Underlying Prediction Of Weight Loss By Premorbid...mentioning
confidence: 99%